Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Cystic Fibrosis Sputum Model

Delafloxacin (DLX) is a recently approved fluoroquinolone with broad activity against common cystic fibrosis (CF) pathogens, including multidrug-resistant Pseudomonas aeruginosa (MDR-Psa). Delafloxacin has been previously shown to have excellent lung and biofilm penetration and enhanced activity at...

Descripción completa

Detalles Bibliográficos
Autores principales: Craddock, Vaughn D., Steere, Evan L., Harman, Hannah, Britt, Nicholas S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295321/
https://www.ncbi.nlm.nih.gov/pubmed/37370396
http://dx.doi.org/10.3390/antibiotics12061078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295321/
https://www.ncbi.nlm.nih.gov/pubmed/37370396
http://dx.doi.org/10.3390/antibiotics12061078

Ejemplares similares